Form 4: Milestone Pharma CFO Reports Insider Stock Transactions

Milestone Pharmaceuticals' CFO, Amit Hasija, reported recent stock option grants, RSU and PSU vestings, and subsequent share sales to cover tax liabilities.

Summary

• Amit Hasija, CFO & EVP of Corporate Development at Milestone Pharmaceuticals Inc. (MIST), reported several transactions.
• On December 12, 2025, 100,000 Performance Stock Units (PSUs) vested following FDA approval of Cardamyst (etripamil).
• Also on December 12, 2025, Hasija was granted 100,000 employee stock options with an exercise price of $1.74, vesting 50% on June 12, 2026, and 50% on December 12, 2026.
• On December 15, 2025, 58,007 common shares were sold at a weighted average price of $2.32 per share to satisfy income tax liabilities from PSU vesting.
• On January 26, 2026, 20,100 Restricted Stock Units (RSUs) vested.
• On January 26, 2026, 12,245 common shares were sold at a weighted average price of $1.93 per share to satisfy income tax liabilities from RSU vesting.
• Following these transactions, Hasija beneficially owns 99,848 direct common shares and 60,300 direct derivative securities (RSUs).
• The transactions were made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The vesting of PSUs due to FDA approval is a strong positive, indicating a significant company achievement. The grant of new options also aligns management incentives. The sales are 'sell-to-cover' for tax purposes, which is a neutral, expected event rather than a negative signal of lack of confidence.

Positives

• The vesting of 100,000 PSUs on December 12, 2025, was triggered by the U.S. FDA's New Drug Application Approval Letter for Cardamyst (etripamil), indicating a significant regulatory milestone for the company.
• The grant of 100,000 employee stock options on December 12, 2025, with an exercise price of $1.74, suggests continued alignment of management's interests with shareholder value creation.

Negatives

• Amit Hasija sold 58,007 common shares on December 15, 2025, at a weighted average price of $2.32 per share.
• Amit Hasija sold an additional 12,245 common shares on January 26, 2026, at a weighted average price of $1.93 per share.
• These sales were 'sell-to-cover' transactions, meaning they were executed to satisfy income tax liabilities incurred upon the vesting of PSUs and RSUs, which is a common practice but still represents a reduction in direct share ownership.

Risks

• Future vesting of the employee stock options and Restricted Stock Units (RSUs) is subject to the reporting person continuing to provide service through the specified vesting dates, posing a risk of forfeiture if employment ceases.
• The value of the vested shares and options is subject to market fluctuations, impacting the ultimate realized value for the reporting person and potentially influencing future sell-to-cover decisions.

Future Outlook

Future outlook includes the vesting of 50% of employee stock options on June 12, 2026, and the remaining 50% on December 12, 2026. Additionally, the remaining Restricted Stock Units (RSUs) will vest in equal one-fourth (1/4th) installments on January 26, 2027, January 26, 2028, and January 26, 2029, all contingent on continued service.

Industry Context

This Form 4 filing details routine insider transactions for a pharmaceutical company executive. The vesting of Performance Stock Units (PSUs) tied to FDA approval of Cardamyst (etripamil) is a significant event within the biopharmaceutical industry, indicating successful progression of a drug candidate through regulatory hurdles. Such approvals are critical value drivers for biotech firms, distinguishing them from competitors with less advanced pipelines.

Comparison to Industry Standards

• The 'sell-to-cover' mechanism for satisfying tax liabilities upon equity award vesting is a standard practice across industries, including pharmaceuticals, and is not indicative of a unique company-specific issue.
• The grant of performance-based equity (PSUs) tied to regulatory milestones like FDA approval is a common incentive structure in the biotech sector, aligning executive compensation with key strategic achievements, similar to practices at companies like Pfizer or Moderna for drug development milestones.
• The vesting schedule for employee stock options and RSUs over several years is typical for executive compensation packages in publicly traded companies, designed to promote long-term retention and performance, comparable to structures seen at companies such as Johnson & Johnson or Merck.

Related Party Transactions

• The reported transactions involve the CFO of Milestone Pharmaceuticals Inc. acquiring and disposing of company securities, which are inherently related-party transactions as they involve an insider.

Stakeholder Impact

• Shareholders: The FDA approval leading to PSU vesting is a positive signal for the company's drug pipeline and potential future revenue, which could positively impact share value. Insider sales, even for tax purposes, can sometimes be perceived negatively, but these are routine for equity compensation.
• Employees: The vesting of equity awards and grant of new options for a key executive can serve as a positive example of compensation and retention strategies within the company.
• Regulatory Authorities: The filing demonstrates compliance with Section 16(a) of the Securities Exchange Act of 1934 regarding insider trading disclosures.

Next Steps

• 50% of the employee stock options will vest on June 12, 2026.
• The remaining 50% of the employee stock options will vest on December 12, 2026.
• One-fourth (1/4th) of the RSU award will vest on January 26, 2027, January 26, 2028, and January 26, 2029, respectively.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Performance Stock Units, FDA Approval, Cardamyst, Etripamil, Sell-to-cover, Executive Compensation